Shots:

• The company has received the US FDA’s clearance for the IND application to expand an ongoing P-I dose escalation and expansion trial to evaluate the safety and tolerability of NX-1607 in adults with advanced malignancies incl. a range of solid tumor indications
• Patients are now being enrolled in the trial in the UK with clinical sites in the US being added later. The result from initial biomarker data from the P-I trial are expected in H1’22
• NX-1607 is an orally bioavailable inhibitor of CBL-B for immuno-oncology indications incl. a range of solid tumor types. Additionally, the therapy showed single-agent anti-tumor activity in multiple tumor models

Ref: Nurix | Image: Nurix